Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Rescheduling Marijuana: The biggest catalyst for 2015

Jan 13, 2015 • 1:43 PM EST
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

The marijuana industry is at a turning point. The major catalyst for the marijuana industry during 2015 is the rescheduling of marijuana out of its current Schedule I classification. In late October, U.S District Judge Kimberly Mueller listened to testimonies during a five day evidentiary hearing aimed at determining if the Schedule I dangerous drug is unconstitutional.

The rescheduling of marijuana will create a domino effect for the entire cannabis industry. Soon after marijuana is rescheduled, the Treasury Department will come out with a memorandum which will set rules and regulations for working with marijuana businesses. Once these businesses are able to use banks, not only will the business become less risky but it will also become more profitable!


Judge Mueller is expected to announce her verdict later this year. The case marks the first time in decades that a judge has agreed to consider marijuana’s designation as a Schedule I drug under the 1970 Controlled Substances Act. Schedule I substances are those that have the following findings:

  • The drug or substance has a high potential for abuse.

  • The drug or substance has no currently accepted medical use in treatment in the United States.

  • There is a lack of accepted safety for use of the drug or substance under medical supervision


Technial420 expects that Judge Mueller’s verdict will be in favor of cannabis NOT being a Schedule I substance. The reason why we are confident in this is because:

  1. On the third day of the hearing, both federal prosecutors and the defense agreed that cannabis has medicinal benefits. This completely contradicts the definition of a Schedule 1 substance.

  2. Research has shown that cannabis has medical benefits. GW Pharmaceutical (GWPH: NASDAQ) has developed a variety of drugs that treat illnesses which were derived from the cannabis plant. These drugs are currently sold in over 25 countries!

  3. Medical experts such as Dr. Sanjay Gupta have stated that marijuana has medical benefits.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.